Home > Annual Financials > CONCORD DRUGS

CONCORD DRUGS Financial Statement Analysis
[BOM: 538965]

The Revenues of CONCORD DRUGS have increased by 0.71% YoY .
The Earnings Per Share (EPS) of CONCORD DRUGS has decreased by -27.66 % YoY.
COMMUNITY POLL
for CONCORD DRUGS
Please provide your vote to see the results

CONCORD DRUGS Last 5 Annual Financial Results
[BOM: 538965]

ConsolidatedMar2025
Mar2024
Mar2023
Mar2022
Revenues ₹45 Cr₹45 Cr₹52 Cr₹59 Cr
Expenses ₹41 Cr₹41 Cr₹48 Cr₹53 Cr
Operating Profit (Excl OI) ₹4.14 Cr₹4.04 Cr₹4.57 Cr₹5.59 Cr
Other Income ₹0.01 Cr₹0.01 Cr₹0.01 Cr₹0.10 Cr
Interest ₹2.03 Cr₹1.87 Cr₹1.71 Cr₹1.68 Cr
Depreciation ₹1.43 Cr₹1.56 Cr₹1.63 Cr₹1.77 Cr
Profit Before Tax ₹0.69 Cr₹0.63 Cr₹1.25 Cr₹2.25 Cr
Profit After Tax ₹0.34 Cr₹0.47 Cr₹0.99 Cr₹1.59 Cr
Consolidated Net Profit ₹0.34 Cr₹0.47 Cr₹0.99 Cr₹1.59 Cr
Earnings Per Share (Rs)₹0.34₹0.47₹1.06₹1.82
PAT Margin (%)0.741.051.892.70
ROE(%)0.991.453.315.62
ROCE(%)5.194.996.328.77
Total Debt/Equity(x)0.560.520.540.58

Key Financials

Market Cap : ₹ 99.5 Cr
Revenue (TTM) : ₹ 78.8 Cr
Net Profit(TTM) : ₹ 1.1 Cr
EPS (TTM) : ₹ 0.8
P/E (TTM) : 94.5

Industry Peers & Returns1W1M1Y
CONCORD DRUGS -0.3% -6.2% 124.7%
SUN PHARMACEUTICAL INDUSTRIES 2.7% 7.5% 12.8%
DIVIS LABORATORIES 4.2% 3.9% 1.5%
TORRENT PHARMACEUTICALS 4.3% 11.2% 42.5%
CIPLA 0.4% 5.3% -3%
DR REDDYS LABORATORIES 0.9% 8% 5.6%
MANKIND PHARMA -0.3% 7.9% 8.4%
LUPIN 3% 10.8% 27.8%
ZYDUS LIFESCIENCES 3.2% 5.8% 16.2%


CONCORD DRUGS Revenues
[BOM: 538965]

Y-o-Y

0.71 %

5 Yr CAGR

-8.45 %

Years Revenues % Change
Mar2025 ₹45 Cr
0.71
Mar2024 ₹45 Cr
-13.74
Mar2023 ₹52 Cr
-11.66
Mar2022 ₹59 Cr -


CONCORD DRUGS Operating Profit
[BOM: 538965]

Y-o-Y

2.28 %

5 Yr CAGR

-9.58 %

Years Operating Profit % Change
Mar2025 ₹4.14 Cr
2.28
Mar2024 ₹4.04 Cr
-11.57
Mar2023 ₹4.57 Cr
-18.25
Mar2022 ₹5.59 Cr -

Operating Margins
Y-o-Y

1.56 %

5 Yr CAGR

-1.24 %

Years Operating Margin% % Change
Mar2025 9.14%
1.56
Mar2024 9%
2.51
Mar2023 8.78%
-7.48
Mar2022 9.49% -

CONCORD DRUGS Profit After Tax
[BOM: 538965]

Y-o-Y

-28.81 %

5 Yr CAGR

-40.49 %

Years Profit After Tax % Change
Mar2025 ₹0.34 Cr
-28.81
Mar2024 ₹0.47 Cr
-52.13
Mar2023 ₹0.99 Cr
-38.14
Mar2022 ₹1.59 Cr -

PAT Margins
Y-o-Y

-29.52 %

5 Yr CAGR

-35.04 %

Years PAT Margin(%) % Change
Mar2025 0.74 %
-29.52
Mar2024 1.05 %
-44.44
Mar2023 1.89 %
-30.00
Mar2022 2.7 % -

CONCORD DRUGS Earnings Per Share (EPS)
[BOM: 538965]

Y-o-Y

-27.66 %

5 Yr CAGR

-42.83 %

Years EPS % Change
Mar2025 ₹0.34
-27.66
Mar2024 ₹0.47
-55.66
Mar2023 ₹1.06
-41.76
Mar2022 ₹1.82 -

CONCORD DRUGS Return on Capital Employed (ROCE)
[BOM: 538965]

Y-o-Y

4.01 %

5 Yr CAGR

-16.04 %

Years ROCE % Change
Mar2025 5.19%
4.01
Mar2024 4.99%
-21.04
Mar2023 6.32%
-27.94
Mar2022 8.77% -

CONCORD DRUGS Share Price vs Sensex

Current Share Price : ₹75.4
Current MarketCap: ₹ 99.5 Cr
Updated EOD on :Jul 06,2026

Share Price Returns(%) 1 Week 1 Month 1 Year
CONCORD DRUGS

-0.3%

-6.2%

124.7%

SENSEX

2%

5.3%

-6.5%

CONCORD DRUGS related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about CONCORD DRUGS Financials


How the annual revenues of CONCORD DRUGS have changed ?

The Revenues of CONCORD DRUGS have increased by 0.71% YoY .

How the Earnings per Share (EPS) of CONCORD DRUGS have changed?

The Earnings Per Share (EPS) of CONCORD DRUGS has decreased by -27.66 % YoY .